ABLI Stock Overview
Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Abliva AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.44 |
| 52 Week High | SEK 0.44 |
| 52 Week Low | SEK 0.11 |
| Beta | 0.95 |
| 1 Month Change | 3.67% |
| 3 Month Change | 176.20% |
| 1 Year Change | 87.37% |
| 3 Year Change | -16.11% |
| 5 Year Change | -64.66% |
| Change since IPO | -93.27% |
Recent News & Updates
Recent updates
Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?
Oct 02
Abliva (STO:ABLI) Is In A Strong Position To Grow Its Business
Dec 18Here's Why We're A Bit Worried About Abliva's (STO:ABLI) Cash Burn Situation
Aug 24Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?
Aug 21We're Keeping An Eye On Abliva's (STO:ABLI) Cash Burn Rate
Oct 13Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?
Mar 22How Much Is Abliva AB (publ) (STO:ABLI) Paying Its CEO?
Dec 06Shareholder Returns
| ABLI | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 1.0% | 1.5% | 1.1% |
| 1Y | 87.4% | 18.9% | 14.0% |
Return vs Industry: ABLI exceeded the Swedish Biotechs industry which returned 19.2% over the past year.
Return vs Market: ABLI exceeded the Swedish Market which returned 13.5% over the past year.
Price Volatility
| ABLI volatility | |
|---|---|
| ABLI Average Weekly Movement | 59.7% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: ABLI's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: ABLI's weekly volatility has increased from 31% to 60% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 6 | Ellen Donnelly | abliva.com |
Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic complications. It has a licensing and collaboration agreement with Owl Therapeutics for NeuroSTAT for the treatment of traumatic brain injury; and Yungjin Pharm on the clinical development of the KL1333, as well as Isomerase, Children’s Hospital of Philadelphia, Newcastle University and University College London, and Oroboros Instruments.
Abliva AB (publ) Fundamentals Summary
| ABLI fundamental statistics | |
|---|---|
| Market cap | SEK 705.20m |
| Earnings (TTM) | -SEK 88.71m |
| Revenue (TTM) | SEK 137.00k |
5,147x
P/S Ratio-7.9x
P/E RatioIs ABLI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABLI income statement (TTM) | |
|---|---|
| Revenue | SEK 137.00k |
| Cost of Revenue | SEK 68.29m |
| Gross Profit | -SEK 68.15m |
| Other Expenses | SEK 20.56m |
| Earnings | -SEK 88.71m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 21, 2025
| Earnings per share (EPS) | -0.055 |
| Gross Margin | -49,744.53% |
| Net Profit Margin | -64,751.09% |
| Debt/Equity Ratio | 0% |
How did ABLI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 09:18 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Abliva AB (publ) is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrik Ling | DNB Markets |
| Jonas Peciulis | Edison Investment Research |
| Ludvig Svensson | Penser Access |